Clinical Trials in Pennsylvania

Showing 6581-6600 of 19,675 trials

Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

NCT03246074

This research is being done to test the safety of the combination of the study drugs fostamatinib and paclitaxel. This study tests different doses of the drugs to see which doses are safest in people with ovarian cancer when given together.

Ovarian Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35 participantsStarted Apr 2018

Washington D.C., District of Columbia, United States • Baltimore, Maryland, United States • Philadelphia, Pennsylvania, United States

COMPLETEDPhase 395 miles

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

NCT01877655

The purpose of the study was to evaluate the efficacy of ASP0113 compared with placebo as measured by a primary composite endpoint of overall mortality and CMV end organ disease (EOD) through 1 year post-transplant. Safety of ASP0113 in participants undergoing allogeneic HCT will also be evaluated.

Cytomegalovirus (CMV)-Positive RecipientsAllogeneic, Hematopoietic Cell Transplant (HCT)

Astellas Pharma Global Development, Inc.514 participantsStarted Sep 2013

Birmingham, Alabama, United States • Tucson, Arizona, United States • San Francisco, California, United States +80 more locations

Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)

Find Trials by Condition in Pennsylvania

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen Planus

Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19

Network Interventions to Reduce Disparities in Living Kidney Donation

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

Pediatric Arthritis Study of Certolizumab Pegol

Trial Comparing Peripheral I.V. Catheter Complication Rates of Two Different Catheter Dressings

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms